{"nctId":"NCT00605280","briefTitle":"A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension.","startDateStruct":{"date":"2005-09"},"conditions":["Macular Edema Associated With Diabetes Mellitus"],"count":317,"armGroups":[{"label":"Sham Control","type":"SHAM_COMPARATOR","interventionNames":["Drug: Standard of Care"]},{"label":"Macugen","type":"EXPERIMENTAL","interventionNames":["Drug: Macugen"]}],"interventions":[{"name":"Standard of Care","otherNames":[]},{"name":"Macugen","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* macular edema associated with diabetes\n* visual acuity between 20/50 and 20/200\n\nExclusion Criteria:\n\n* recent laser therapy in the eye\n* recent signs of uncontrolled diabetes\n* blood pressure worse than 160/100\n* severe cardiac disease","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Greater Than or Equal to ≥10 Letter (or 2 Line) Improvement in Vision at 1 Year","description":"Refraction and best-corrected visual acuity (VA) measurements were performed using retro-illuminated, modified Ferris-Bailey Early Treatment Diabetic Retinopathy Study (ETDRS) charts","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With a ≥ 10 Letter (or 2 Line) Improvement in Vision at 2 Years","description":"Refraction and best-corrected VA measurements were performed using retro-illuminated, modified Ferris-Bailey ETDRS charts","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"37","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With a ≥ 15 Letter Improvement in Vision at 1 Year","description":"Refraction and best-corrected VA measurements were performed using retro-illuminated, modified Ferris-Bailey ETDRS charts","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With a ≥ 15 Letter Improvement in Vision at 2 Years","description":"Refraction and best-corrected VA measurements were performed using retro-illuminated, modified Ferris-Bailey ETDRS charts","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Eyes With a 2 or More Step Increase in Degree of Retinopathy at 1 Year","description":"Retinopathy changes were monitored using fundus photography and fluorescein angiograph (FA) assessments. An Independent Reading Center, using trained graders, evaluated the presence of retinopathy using a modified 12-step version of the ETDRS Final Retinopathy Severity Scale, that ranged from step 1 (retinopathy level of 10 or 12) to step 12 (retinopathy level of 85A or 85B) where an increase in the step or retinopathy level indicated a worsening of the condition.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Eyes With a 2 or More Step Decrease in Degree of Retinopathy at 1 Year","description":"Retinopathy changes were monitored using fundus photography and FA assessments. An Independent Reading Center, using trained graders, evaluated the presence of retinopathy using a modified 12-step version of the ETDRS Final Retinopathy Severity Scale, that ranged from step 1 (retinopathy level of 10 or 12) to step 12 (retinopathy level of 85A or 85B) where a decrease in the step or retinopathy level indicated an improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Eyes With a 2 or More Step Increase in Degree of Retinopathy at 2 Years","description":"Retinopathy changes were monitored using fundus photography and FA assessments. An Independent Reading Center, using trained graders, evaluated the presence of retinopathy using a modified 12-step version of the ETDRS Final Retinopathy Severity Scale, that ranged from step 1 (retinopathy level of 10 or 12) to step 12 (retinopathy level of 85A or 85B) where an increase in the step or retinopathy level indicated a worsening of the condition.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Eyes With a 2 or More Step Decrease in Degree of Retinopathy at 2 Years","description":"Retinopathy changes were monitored using fundus photography and FA assessments. An Independent Reading Center, using trained graders, evaluated the presence of retinopathy using a modified 12-step version of the ETDRS Final Retinopathy Severity Scale, that ranged from step 1 (retinopathy level of 10 or 12) to step 12 (retinopathy level of 85A or 85B) where a decrease in the step or retinopathy level indicated an improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Mean VA Score at 1 Year","description":"Changes in VA monitored through refraction and best-corrected VA measurements using retro-illuminated, modified Ferris-Bailey ETDRS chart with participants at a 4-meter distance from chart. Distance VA expressed as an ETDRS score (number of letters correctly read) ranging from 0 to 60, where higher ETDRS scores represented better vision. Change from baseline for each patient equaled the visual acuity obtained at the observation minus the visual acuity at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.0","spread":"8.85"},{"groupId":"OG001","value":"57.5","spread":"8.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.2","spread":"9.94"},{"groupId":"OG001","value":"1.2","spread":"11.77"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Mean VA Score at 2 Years","description":"Changes in VA monitored through refraction and best-corrected VA measurements using retro-illuminated, modified Ferris-Bailey ETDRS chart with participants at a 4-meter distance from chart. Distance VA expressed as an ETDRS score (number of letters correctly read) ranging from 0 to 60, where higher ETDRS scores represented better vision. Change from baseline for each patient equaled the visual acuity obtained at the observation minus the visual acuity at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.0","spread":"8.85"},{"groupId":"OG001","value":"57.4","spread":"8.20"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.2","spread":"10.58"},{"groupId":"OG001","value":"1.7","spread":"11.68"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Requiring Focal or Grid Laser Treatment During Year 1","description":"Included focal laser coagulation, focal laser photocoagulation, panretinal laser photocoagulation, retinal laser coagulation, and retinal laser photocoagulation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"53","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Requiring Focal or Grid Laser Treatment During Year 2","description":"Included focal laser coagulation, focal laser photocoagulation, panretinal laser photocoagulation, retinal laser coagulation, and retinal laser photocoagulation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"57","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":42,"n":174},"commonTop":["Conjunctival haemorrhage","Intraocular pressure increased","Macular oedema","Diabetic retinal oedema","Eye pain"]}}}